Biofrontera, Bipharma B.V. deal

Biofrontera granted Bipharma exclusive rights to market actinic keratosis drug Ameluz ( BF-200 ALA) in the Netherlands, Belgium and Luxembourg. Biofrontera will receive a €100,000 ($133,640) upfront payment, plus "a very significant share of all net revenues" of Ameluz generated by Bipharma. Biofrontera will be responsible for regulatory approval, manufacturing and quality control of Ameluz. Bipharma is obligated to launch the product in the Netherlands no later than Nov. 1. ...